STTCOMP BIT FA LongMC 68MSOI 701,932,713Cash 5.8M Now that it is coming closer to when Biotron will release their initial COVID-19 trial results, it is time to spill the beans on what I believe is the possible cure. This is based on information obtained from Biotron's previously published works.
https://patentimages.storage.googleapis.com/b4/2f/4c/3793695c1bd528/WO2004112687A2.pdf page 16.
This image of the compound cinnamoylguanidine is taken from Biotron's first patent in 29/12/2004 by the World Intellectual Property Organization, and can also be found in following US patents in 2004, 2005, 2012, 2015, 2017, and the latest on December 26th, 2019,
The importance of cinnamoylguanidine or one of its derivatives, of which there are many, in Biotrons library of small molecule antiviral compounds, cannot be underestimated as a potential cure for COVOD-19. This is because cinnamoyleguanidine blocked most ion channel activity in the E protein of SARS-CoV-1 (SARS) and two other human coronavirus strains, 229E and OC43.
The E protein is the smallest of the four essential proteins that make up all RNA coronavirus envelopes, and has the function of viral replication. Biotron is credited in 2003 for discovering that the E Protein is a voroporin, that is, a protein where ion channel activity across lipid bylayers. This is crucial for viral replication within host cells, as demonstrated in their most recent patent of December 2019.
Once SARS-CoV-1 was contained in 2003, Biotron adapted the technology to HIV research, which in 2018 demonstrated that HIV infected persons responded well to treatment of BIT225, their main HIV drug candidate, in conjunction with other HIV antiretroviral drugs. The positive immunological response by test patients was caused by the "eradication of virus frommacrophage reservoir cells." https://www.biotron.com.au/wp-content/uploads/2018/09/Significant-Immunological-Outcomes-in-BIT225-HIV-1-Clinical-Trial.pdf
Since the end of the Phase 2 HIV trials, Biotron have been analyzing data to determine the mechanisms in which the patients immunological response occurred, and have had patents published covering all aspects of their compounds and methodology regarding the work and in treating viruses, including coronaviruses.
The following two diagram shows the SARS-COV-1 E protein ion channel activity in a natural state and after treated with BIT036 respectively. As can be seen in the second diagram, BIT036 inhibits ion channel activity, as shown by the single straight line, whereas the first diagram shows the high ion electrical/ion acitivity. The result of this is that viral replication can be halted as has been similarly achieved with the Vpu ion channel activity in HIV.
http://www.freepatentsonline.com/20190389816.pdf
Presently, Biotron is conducting tests on their antiviral compounds in conjunction with the Peter Doherty Institute as announced on Febuary 6th, 2020.https://www.biotron.com.au/wp-content/uploads/2020/02/Biotron-to-Test-its-Compounds-Against-Coronavirus.pdf
The outcome of these trials will be released in the near future, and considering the success in inhibiting ion channel activity in the SARS-CoV-1 E protein, as well as in other human coronaviruses using cinnamoylguanidine, I am expecting that similar results can be achieved against SARS-CoV-2, which will then lead to acure for COVID-19.What is important here is that the E Protein of both strains of the virus are identical, unlike the S Protein where many mutations have already occurred.
